Journal
NATURE COMMUNICATIONS
Volume 12, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-021-27076-z
Keywords
-
Categories
Funding
- Engineering and Physical Sciences Research Council [EP/M508056/1]
- Medical Research Council [G0801566, G0901213-92157, MC_PC_16045, MC_UU_12014/1, MR/K013491/1]
- Wellcome Trust [102789/Z/13/A]
- NHS Research Scotland (NRS) Greater Glasgow and Clyde Biorepository
- MRC [MC_UU_12014/1, G0801566, MC_PC_16045, MR/K013491/1] Funding Source: UKRI
- Wellcome Trust [102789/Z/13/A] Funding Source: Wellcome Trust
Ask authors/readers for more resources
The study introduces a pan-genotypic RNA assay for HCV detection, based on reverse transcriptase loop mediated isothermal amplification, and a low-cost point-of-care device that provides visually-read results quickly. The assay meets WHO guidelines, is manufactured using simple portable equipment, and can improve patient care pathways and reduce loss to follow-up, contributing to the global elimination of HCV.
Current HCV nucleic acid-based diagnosis is largely performed in centralised laboratories. Here, the authors present a pan-genotypic RNA assay, based on reverse transcriptase loop mediated isothermal amplification and develop a low-cost prototype paper-based lateral flow device for point-of-care use, providing a visually read result within 40 min. The early diagnosis of active hepatitis C virus (HCV) infection remains a significant barrier to the treatment of the disease and to preventing the associated significant morbidity and mortality seen, worldwide. Current testing is delayed due to the high cost, long turnaround times and high expertise needed in centralised diagnostic laboratories. Here we demonstrate a user-friendly, low-cost pan-genotypic assay, based upon reverse transcriptase loop mediated isothermal amplification (RT-LAMP). We developed a prototype device for point-of-care use, comprising a LAMP amplification chamber and lateral flow nucleic acid detection strips, giving a visually-read, user-friendly result in <40 min. The developed assay fulfils the current guidelines recommended by World Health Organisation and is manufactured at minimal cost using simple, portable equipment. Further development of the diagnostic test will facilitate linkage between disease diagnosis and treatment, greatly improving patient care pathways and reducing loss to follow-up, so assisting in the global elimination strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available